Benzinga | Sep 30, 2020 07:36AM EDT

Scholar Rock To Present Data For SRK-015 At The World Muscle Society 2020 Virtual Congress Oct. 1

Scholar Rock (NASDAQ:SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced two poster presentations as part of the World Muscle Society (WMS) 2020 Virtual Congress. The SRK-015 clinical development poster will showcase previously presented data from the Phase 1 healthy volunteer trial, as well as baseline characteristics and demographics from the TOPAZ Phase 2 proof-of-concept trial evaluating SRK-015 for the treatment of patients with Type 2 and Type 3 Spinal Muscular Atrophy (SMA). The second poster shares data on the pharmacologic effects of SRK-015 in patients with SMA, healthy volunteers, and across animal species.

Details for the two virtual posters at the WMS meeting are as follows:

* Title: Clinical Development of SRK-015, a Fully Human Anti-proMyostatin Monoclonal Antibody, for the Treatment of Later-Onset Spinal Muscular Atrophy

* Title: Myostatin Dynamics in Health and Disease: Pharmacologic Effects of SRK-015, a Highly Selective Monoclonal Antibody Inhibitor of Myostatin Activation

* Virtual poster presentations on October 1, 2020 at 17:30-19:30 BST.

The SRK-015 TOPAZ Phase 2 clinical trial is fully enrolled, and a 6-month interim efficacy and safety analysis is planned for the fourth quarter of 2020 with top-line data for the 12-month treatment period expected in the first half of 2021. As of September 25, 2020, 22 patients across the three cohorts have completed the 12-month treatment period, and all 22 have opted into the 12-month extension period.